**Latin American Journal of Clinical Sciences and Medical Technology is an open access magazine.

To read all published articles and materials you just need to register

Registration is free of charge.   Register now

If you already have registered please   Log In
**
Latin American Journal of Clinical Sciences and Medical Tecnology
Thursday July 2nd, 2020
Mission. To accessibly present interesting topics and original research in clinical sciences by means of procedures and digital technology which are friendly for authors, reviewers, and the reader.
Vision. To create a forum to discuss relevant topics and to spread out the original clinical research produced in Latin America. In that way, we will foster the development of high-quality research and publication in Latin-America in order to make visible the expertise and evidence our clinicians all over the world.
Objective. To be an effective and state-of-the-art tool for spreading Latin American original research with the best visibility, availability, and legibility that will ensure an increase in the number, quality and citation of the Latin American region. Based on that, our journal will contribute to improve the comprehension of basic concepts for the use of the latest diagnosis and treatment resources.
Submit
& Guide
for Authors
Authors
Access
Reviewers
Access
Editorial
Board
Current
Issue
Previous
Issue
Societies
DADI
Salud
Contact Us
Latin American Journal of Clinical Sciences and Medical Technology is an international, Open Access magazine, which quarterly publishes articles in Spanish and in English, and it is spread out online and in printed versions. It is a scientific, academic tool focused on original Latin-American research, as well as on subjects of interest that will undoubtedly enrich the continuing medical education in the aforementioned geographical area.

Cladribina para el tratamiento de la esclerosis múltiple remitente recurrente: nueva alternativa para Latinoamérica

Yamel Rito, Verónica Rivas-Alonso, Erwin Chiquete

Cladribina es una desoxiadenosina modificada que evade la acción de la enzima desaminasa de adenosina, lo que resulta en un efecto inmunosupresor por linfopenia y en la consecuente reconstitución de las células del sistema inmune. Entonces, es un fármaco que ayuda al tratamiento de enfermedades autoinmunes como la esclerosis múltiple remitente recurrente (EMRR). Debido a que en la actualidad contamos con una amplia gama de medicamentos para tratar la EMRR, es de gran interés para nosotros identificar el papel que desempeña cladribina entre todas las opciones. El objetivo principal de esta revisión es el de proporcionar información útil, con el apoyo de un caso clínico de estudio, que ayude a los médicos en la toma de decisiones para tratar a los pacientes con EMRR y brindarles las mejores opciones de eficacia y seguridad. Por sus efectos inmunosupresores selectivos, cladribina está indicada para el tratamiento de EMRR de actividad moderada a grave, ya sea en tratamiento de escalada o de inducción. En este artículo se analizarán las características de dicho medicamento para establecer las bases científicas que guíen la toma de decisiones terapéuticas, tomando en cuenta el equilibrio de riesgos y beneficios para el paciente.

Learn more

Descending Cervical-Sacral Pain after the Administration of Antivenom to the Scorpion Sting Poisoning: A Case Report

Josué Saúl Almaraz Lira, Alfredo Luis Chávez Haro, Cristian Alfredo López López, Remedios del Pilar González Jiménez

Introduction. Scorpion stings occur mainly in spring and summer, with an estimate of approximately 1.2 million cases per year worldwide. About 300,000 poisonings occur within a year, primarily affecting children and adults older than 65 years. In 2019, Guanajuato (Mexico) ranked third in poisoning by scorpion sting with a total of 43,913 cases. The intoxication grades are three where the signs and symptoms are varied. There are two types of antivenom in the Mexican market, and we use Alacramyn® in our case. Case presentation. A 70-year-old female —with grade 1 scorpion sting poisoning, 30 minutes of evolution, with type 2 diabetes and high blood pressure— received two vials of antivenom according to current regulations. She presented transient vagal reaction and subsequent transient pain in the cervical region that radiates to the sacral region. At discharge, there are no data compatible with scorpion sting poisoning. Conclusions. Transient pain in the cervical region to the sacral region may be secondary to an anxiety crisis, hypersensitivity to IgG, or secondary reaction to administration in less time than recommended by the provider. The benefit was greater than the reactions that occurred.

Learn more

Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers

Suset J. Tolentino-Hernández, Leticia Cruz-Antonio, Irma Torres-Roque, José T. Pérez-Urizar

Introduction. Oral ciprofloxacin extended-release formulation decreases the risk of treatment failure and prevents the development of antimicrobial resistance. However, non-equivalent formulations lead to subtherapeutic plasma drug concentrations, increasing the risk of such problems. Objective. To determine the bioequivalence of two oral ciprofloxacin extended-release tablet formulations (1,000 mg) in healthy Mexican volunteers. Material and methods. In this open-label 2 x 2 crossover design study, 26 healthy volunteers were randomly allocated to receive a single dose of the reference drug Cipro XR® (Bayer, Mexico) and the test formulation Ciproflox DM® (Senosiain Laboratories, Mexico). Blood samples were obtained for 24 hours. Ciprofloxacin plasma levels were quantified using a validated liquid chromatography method. Pharmacokinetic parameters were obtained by standard non-compartmental analysis. In order to determine bioequivalence, log-transformed test/reference ratios of Cmax, AUC0-t, and AUC0-inf were compared by an analysis of variance, followed by the 90% confidence intervals and the Schuirmann bilateral test. Results. The 90% confidence intervals ranged from 85.69 to 114.31% for Cmax, 85.16-115.84 % in AUC0-t,and 85.39-114.61% for AUC0-inf, all cases were within bioequivalence acceptance criteria (80-125%). Schuirmann test verified the probability that the values were within these criteria (p<0.05). No side-effects were observed with any treatment. Conclusions. The results obtained demonstrate bioequivalence between the analyzed formulations.

Learn more

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology, Año 1, No. 1, octubre, 2019 es una publicación mensual editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez, calle San Luis Potosí # 182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.
Contact us   |   Privacy policy   |   Legal Information

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology, Año 1, No. 1, octubre, 2019 es una publicación mensual editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez, calle San Luis Potosí # 182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.